volume 20, issue 3, P581-607 2006
DOI: 10.1016/j.idc.2006.06.003
View full text
|
|
Share
Dimitrios P. Kontoyiannis, Russell E. Lewis

Abstract: Zygomycosis is an increasingly common infection in immunocompromised patients. Advances in the understanding of Zygomycetes pathobiology and the introduction of new drugs with improved activity and tolerability for treatment of zygomycosis have improved the prospects of effectively controlling this devastating infection. Further reductions in mortality will require improved diagnostic and novel therapeutic approaches for this group of aggressive opportunistic molds.